Send to

Choose Destination
See comment in PubMed Commons below
Cancer Sci. 2017 Dec 21. doi: 10.1111/cas.13474. [Epub ahead of print]

The Optimal Cumulative Cisplatin Dose in Nasopharyngeal Carcinoma Patients Receiving Additional Induction Chemotherapy.

Author information

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China.


To clarify the optimal cumulative cisplatin dose (CCD) in locoregionally-advanced nasopharyngel carcinoma (NPC) patients receiving induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT). Using the NPC-specific database from the established big-data intelligence platform at Sun Yat-Sen University Cancer Center, 583 non-disseminated, locoregionally-advanced NPC patients receiving IC plus CCRT were enrolled. Propensity score matching (PSM) analysis was conducted to control for confounding factors.The median CCD was 160 mg/m2 after IC (range, 40-300mg/m2 ); only 74 patients (12.7%) achieved CCD>200 mg/m2 . Patients receiving>200 mg/m2 CCD did not show significantly improved 5-year overall survival (OS) (HR=1.19; 95% confidence intervals [CI] 0.69-2.06,P=0.53) and progression-free survival (PFS) (HR=1.03; 95% CI 0.63-1.68,P=0.92) compared with patients receiving<200 mg/m2 CCD. Further investigations of the potential of median CCD (160 mg/m2 ) to yield survival benefits revealed that there were no significant differences in survival endpoints between patients receiving CCD>160 mg/m2 and CCD<160 mg/m2 in both the original and PSM cohorts. Additionally, subgroup analysis indicated a favourable PFS, but not OS, with higher cisplatin administration in patients with pretreatment Epstein-Barr virus deoxyribonucleic acid (EBV DNA)<1000 copies/ml (HR=0.26, 95% CI 0.07-0.93,P=0.03) and receiving<3 IC cycles (HR=0.59, 95% CI 0.33-1.07,P=0.08). Our analysis of real world data provided references for the optimal CCD in locoregionally-advanced NPC receiving additional IC. The causal relationship between 200 mg/m2 CCD and improved survival was not defined; 160 mg/m2 CCD might be enough. However, for patients with EBV DNA<1000 copy/ml, and receiving<3 IC cycles, higher dose might be necessary. This article is protected by copyright. All rights reserved.


Cumulative cisplatin dose; Induction chemotherapy; Intensity-modulated radiation therapy; Nasopharyngeal carcinoma; Real world data

Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center